The rationale for optimal combination therapy with sipuleucel-T for patients with castration-resistant prostate cancer - Abstract

Immunotherapy encourages the recipient's own immune response to destroy cancer cells, and current evidence suggests that immunotherapies may be most beneficial in early metastatic castration-resistant prostate cancer (mCRPC).

Sipuleucel-T is the first therapeutic cancer vaccine to be approved by both the US Food and Drug Administration and European Medicines Agency for the treatment of asymptomatic or minimally symptomatic mCRPC. Combining immunotherapy with other treatments may have potent anticancer effects; cytoreductive therapies can release tumor antigens and promote a proinflammatory environment that could augment immunotherapies. However, some cytoreductive agents or coadministered drugs may be immunosuppressive. Understanding these interactions between different mCRPC treatment modalities may offer further potential to improve patient outcomes.

Written by:
Mouraviev V, Mariados N, Albala D, Concepcion RS, Shore ND, Sims RB, Emberton M, Pieczonka CM.   Are you the author?
Associated Medical Professionals of New York, Syracuse, NY; Urology Associates, Nashville, TN; Carolina Urologic Research Center, 21st Century Oncology, Myrtle Beach, SC; Dendreon Corporation, Seattle, WA; University College of London, London, UK.

Reference: Rev Urol. 2014;16(3):122-30.


PubMed Abstract
PMID: 25337042

UroToday.com Prostate Cancer Immunotherapy Section